Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as it was."
From left, Matthew Herper, Rick Pazdur, Nicole Gormley, and Harpreet Singh at a STAT event on Friday.
By Elaine Chen
May 30, 2026
Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.
Elaine Chen
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well,…
How the ouster of key officials at the FDA has created anxiety and uncertainty for the developers of rare disease drugs.
It almost feels like the Trump administration is intentionally breaking the FDA, writes Lab Dish columnist Paul Knoepfler.
With the FDA facing upheaval and personnel exits, former commissioner David Kessler sees an opportunity whereby the agency can…
The FDA's new path, the status of animal testing, and other biotech news from The Readout
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its…
